| Cross-resistance among next-generation antiandrogen drugs through the AKR1C3/AR-V7 axis in advanced prostate cancer J Zhao, S Ning, W Lou, JC Yang, CM Armstrong, AP Lombard, ... Molecular cancer therapeutics 19 (8), 1708-1718, 2020 | 49 | 2020 |
| ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling C Liu, CM Armstrong, S Ning, JC Yang, W Lou, AP Lombard, J Zhao, ... Oncogene 40 (35), 5379-5392, 2021 | 23 | 2021 |
| Steroid sulfatase stimulates intracrine androgen synthesis and is a therapeutic target for advanced prostate cancer CM Armstrong, C Liu, L Liu, JC Yang, W Lou, R Zhao, S Ning, ... Clinical Cancer Research 26 (22), 6064-6074, 2020 | 17 | 2020 |
| Activation of the ABCB1 Amplicon in Docetaxel- and Cabazitaxel-Resistant Prostate Cancer Cells AP Lombard, W Lou, CM Armstrong, LS D'Abronzo, S Ning, CP Evans, ... Molecular cancer therapeutics 20 (10), 2061-2070, 2021 | 14 | 2021 |
| Olaparib-Induced Senescence Is Bypassed through G2–M Checkpoint Override in Olaparib-Resistant Prostate Cancer AP Lombard, CM Armstrong, LS D'Abronzo, S Ning, AR Leslie, M Sharifi, ... Molecular cancer therapeutics 21 (4), 677-685, 2022 | 8 | 2022 |
| Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer JC Yang, P Xu, S Ning, LJ Wasielewski, H Adomat, SH Hwang, ... Oncogene 42 (9), 693-707, 2023 | 6 | 2023 |
| Bioengineered BERA-Wnt5a siRNA targeting Wnt5a/FZD2 signaling suppresses advanced prostate cancer tumor growth and enhances enzalutamide treatment S Ning, C Liu, W Lou, JC Yang, AP Lombard, LS D'Abronzo, N Batra, ... Molecular cancer therapeutics 21 (10), 1594-1607, 2022 | 6 | 2022 |
| Activation of neural lineage networks and ARHGEF2 in enzalutamide-resistant and neuroendocrine prostate cancer and association with patient outcomes S Ning, J Zhao, AP Lombard, LS D’Abronzo, AR Leslie, M Sharifi, W Lou, ... Communications Medicine 2 (1), 118, 2022 | 3 | 2022 |
| Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived models P Xu, JC Yang, S Ning, B Chen, C Nip, Q Wei, L Liu, OT Johnson, AC Gao, ... Pharmacological research 189, 106692, 2023 | 2 | 2023 |
| Wntless expression promotes lineage plasticity and is associated with neuroendocrine prostate cancer LS D’Abronzo, AP Lombard, S Ning, CM Armstong, AR Leslie, M Sharifi, ... American journal of clinical and experimental urology 10 (5), 299, 2022 | 2 | 2022 |
| Therapeutic Resistance Models and Treatment Sequencing in Advanced Prostate Cancer ZA Schaaf, S Ning, AR Leslie, M Sharifi, X Han, C Armstrong, W Lou, ... Cancers 15 (21), 5273, 2023 | 1 | 2023 |
| PD07-02 Targeting Wnt5a/Fzd2 signaling overcomes resistance to enzalutamide in advanced prostate cancer S Ning, C Liu, W Lou, A Lombard, L D'Abronzo, A Yu, C Evans, A Gao The Journal of Urology 207 (Supplement 5), e98, 2022 | 1 | 2022 |
| MP60-17 THERAPEUTIC RESISTANCE MODELS AND TREATMENT SEQUENCING IN ADVANCED PROSTATE CANCER Z Schaaf, S Ning, A Lombard, C Liu, W Lou, A Gao Journal of Urology 211 (5S), e1007, 2024 | | 2024 |
| MP05-11 PINK1 SIGNALING CONFERS OLAPARIB RESISTANCE BY ACTIVATING MITOCHONDRIAL FUNCTION IN ADVANCED PROSTATE CANCER CELLS A Gao, Z Schaaf, S Ning, A Leslie, M Sharifi, A Lombard, W Lou Journal of Urology 211 (5S), e47, 2024 | | 2024 |
| Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer C Liu, B Chen, P Xu, J Yang, C Nip, L Wang, Y Shen, S Ning, Y Shang, ... | | 2024 |
| Dual targeting of HSP70 and AURKA improves treatment in neuroendocrine prostate cancer P Xu, JC Yang, B Chen, S Ning, L Wang, C Nip, CP Evans, MA Dall'Era, ... Cancer Research 84 (6_Supplement), 4567-4567, 2024 | | 2024 |
| The role of PLXND1 in lineage plasticity and progression to neuroendocrine prostate cancer B Chen, P Xu, JC Yang, S Ning, L Wang, C Nip, AC Gao, C Liu Cancer Research 84 (6_Supplement), 3577-3577, 2024 | | 2024 |
| IGFBP3 promotes resistance to Olaparib via modulating EGFR signaling in advanced prostate cancer AR Leslie, S Ning, CM Armstrong, LS D’Abronzo, M Sharifi, ZA Schaaf, ... Iscience 27 (2), 2024 | | 2024 |
| Novel dual inhibitors of AR/AR variants and AKR1C3: Preclinical activities for advanced prostate cancer therapy. A Gao, S Ning, C Armstrong, E Xing, W Lou, PK Li, CP Evans Journal of Clinical Oncology 42 (4_suppl), 169-169, 2024 | | 2024 |
| Abstract B023: Targeting noncanonical Wnt5a signaling suppresses the neural lineage network and overcomes enzalutamide resistance in advanced prostate cancer S Ning, W Lou, C Liu, AP Lombard, LSD Abronzo, N Batra, A Yu, ... Cancer Research 83 (11_Supplement), B023-B023, 2023 | | 2023 |
Allen C GaoUniversity of Califormia DavisVerified email at ucdavis.edu
